Abstract: Vitamin D 3 is beneficial in ameliorating or preventing inflammation and carcinogenesis. Here, we evaluated if vitamin D 3 has a preventive effect on colitis-associated carcinogenesis. Administration of azoxymethane (AOM), followed with dextran sulfate sodium (DSS), was used to simulate colitis-associated colon cancer in mice. 
T he incidence and prevalence of inflammatory bowel disease (IBD) have increased significantly over the last decades in the world. 1 Colorectal cancer (CRC) is one of the most important complications of IBD. Patients with IBD with long, persistent colonic inflammation, and extensive involvement of the colon are at high risk for CRC. The cumulative probability of CRC in patients with ulcerative colitis has shown the range from 2% after 10 years of disease, up to 18% after 30 years of disease. 2 The pathogenesis, progression, chemoprevention, and treatment of colitis-associated cancers (CACs) are different from sporadic CRC. 3 Although CAC accounts for 1% to 2% of CRC, it is one of the leading causes of death in patients with IBD. Since it takes about 20 years to develop CAC, prevention of malignant transformation becomes critical in patients with IBD.
Recently, the relationship between vitamin D and IBD and/or CRC has attracted much attention. Increasing evidence suggests that insufficiency or deficiency of vitamin D is not only one of the risk factors of IBD but also correlated with the IBD disease activity, course, and prognosis. 4, 5 Vitamin D deficiency is likely to occur in patients with IBD and closely associated with the severity of the disease. 6, 7 However, vitamin D is a protective factor against colon cancer. In 1980, it was revealed that CRC mortality rates were highest in places where populations were exposed to the least amount of natural light such as major cities and rural areas in high latitudes. Therefore, it is proposed that vitamin D is a protective factor against colon cancer. 8 In addition, higher plasma levels of 25-hydroxyvitamin D 3 (25[OH]D 3 ) are associated with a lower risk of CRC. 9 Evans et al reported that 1a,25(OH) 2 D 3 synthetic analogs inhibit tumor incidence and spontaneous metastases in a 1,2-dimethylhydrazine-induced colon carcinogenesis model. 10 However, it remains unclear whether vitamin D plays protective role on colitis-associated colon cancer. Here, we investigated the effect of dietary vitamin D intake on CAC in an azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced mouse model.
MATERIALS AND METHODS

AOM-DSS Mouse Model
Male C57BL/6 mice (6-8 weeks old) were fed a standard laboratory diet and kept in an air-conditioned room with day/night cycle (12 hours light, 12 hours dark). Colitis-associated colon cancer was established with the AOM-DSS mouse model as described previously. 11 Briefly, mice were injected intraperitoneally with 12.5 mg/kg AOM (Sigma, A2853). One week later, 2.5% (wt/vol) DSS (MP Biomedicals, 160,110) was given in drinking water for 5 days. All mice were killed at the end of the 14th week. The colons (from the ileocecal junction to the anal verge) were removed and cut open longitudinally along the main axis. After washing with phosphatebuffered saline (pH 7.4), the length and weight of colon were measured and the number, size, and location of colonic neoplasia were record. Mouse colonic tissue was taken from the distal colon and saved with formalin or RNAlater for the further analysis. The study was approved by the Experimental Animal Ethics Committee of the Chinese Academy of Medical Sciences Cancer Institute.
Administration of Vitamin D 3
To evaluate the chemopreventive effect of vitamin D 3 on colitis-associated colon carcinogenesis, vitamin D 3 (Cholecalciferol Cholesterol Emulsion, Shanghai, China) was given intragastrically throughout the experiment at different doses (15, 30 , 60 IU$g 21 $w 21 ) 3 times per week starting before or immediately after AOM and DSS treatment.
Measurement of Serum Levels of 25(OH)D 3 , Calcium, and Creatinine
The blood of mice was collected and centrifuged at 8000 rpm for 5 minutes. The levels of 25(OH)D 3 , calcium, and creatinine in serum were measured and quantified by isotope dilution ultraperformance liquid chromatography tandem mass spectrometry and fully automatic biochemical analyzer at the Department of Clinical Laboratory, Peking Union Medical College Hospital.
Immunohistochemistry
Paraffin sections were deparaffinized and rehydrated through dimethylbenzene and graded concentrations of ethanol solutions. After retrieval of the antigen and blocking endogenous peroxidase activity, the sections were incubated with primary antibodies at 48C overnight followed by Polymer Detection System reagents (ZSGB-BIO company, PV-9000) and DAB (ZLI-9019). Anti-Ki-67 (Abcam, 1:1000), anti-b-catenin (CST, #9582, 1:200), and E-cadherin (CST, 1:400) antibodies were used as the primary antibodies. The slides were analyzed by 2 experienced pathologists in a blinded fashion. The positively stained mucosal cells were counted in 10 randomized fields (·400) with a light microscope (Olympus, Melville, NY), and the average positive rate was taken.
Cell Culture
Human colon cancer cell line SW480 was purchased from ATCC (Manassas, VA). SW480 cells were grown in Dulbecco's modified Eagle's medium/F12 (Hyclone) supplemented with 10% fetal bovine serum (Gibco), 100 U/mL penicillin G, and 100 mg/mL streptomycin and maintained at 378C, 95% humidity, and 5% carbon dioxide. Briefly, 2 · 10 5 cells were seeded onto 6-well plates and incubated for 24 hours for attachment, then treated with either 1a,25 (OH) 2 D 3 (100 nmol/L) (D1530, Sigma) or DMSO for 48 hours. After treatment, the cells were collected for subsequent experiments.
MTT Assays
Cell proliferation in vitro was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In 96-well plates, 10 4 cells were seeded. After 24 hours, the medium was replaced with fresh medium containing serial dilutions of 1a,25(OH) 2 D 3 (1-100 nM). The cells were incubated at 378C for an additional 24 hours, 48 hours, and 72 hours. For the MTT assay, 100 mL of MTT (5 mg/mL) was added to each well. After 4 hours, the MTT was removed and 150 mL of the DMSO was added to each well. After 10 minutes, the absorbance was measured at 490 nm using a microplate reader.
Transient Transfection and Luciferase Assay
SW480 cells in 24-well plates were transfected with a wild type TCF4/LEF 3'UTR reporter (200 ng) and pRL-TK (2 ng). The transfection agent Lipofectamine 2000 (Invitrogen) was incubated in serum-free medium for 20 minutes before being added to cells and incubated for an additional 6 hours. After 48 hours of 1a,25 (OH) 2 D 3 treatment, cell lysate was collected for luciferase activity, which was performed with a Dual-Luciferase assay kit (Promega). All data were normalized by pRL-TK.
RNA Isolation and Real-time Polymerase Chain Reaction
Total RNA was isolated from colon tissue of mice or cancer cells using Trizol reagent (Invitrogen). After treatment with DNase I, RNA was reverse transcribed into cDNA with Thermo scientific maxima first strand cDNA synthesis kit. Real-time quantitative polymerase chain reaction was performed on Bio-Rad S1000 PCR thermocycler, and each sample was analyzed in triplicate. Polymerase chain reaction data were normalized to GAPDH expression for mRNA. 
Immunoprecipitation and Western Blot
Proteins were extracted from cultured cells with radioimmunoprecipitation assay buffer (0.01% EDTA, 0.1% Triton X-100, and 10% proteinase inhibitor mixture). After sonication FIGURE 1. Vitamin D 3 inhibited colon carcinogenesis in a dose-dependent manner in AOM-DSS mouse model. A, Experimental protocol for the colitis-associated carcinogenesis mouse model. C57BL/6 mice received 12.5 mg/kg AOM followed by 5-day 2.5% dextran sulfate sodium (DSS) to induce colitis-associated colon carcinogenesis. Different doses of vitamin D 3 (15, 30 , 60 IU$g 21 $w 21 ) or water were given intragastrically throughout the experiment period. B, Representative hematoxylin and eosin stain of mouse colon from control and AOM-DSS groups. Original magnification is ·40. C, Representative macroscopic view of mouse colon in each group. The formation of colonic tumor was evaluated with (D) tumor number, (E) tumor burden, and (F) tumor percentage in each group. Data were shown as mean 6 SEM (n ¼ 10-12). *P , 0.05, **P , 0.01, ***P , 0.001 versus 0 group. for 30 minutes on ice and centrifuging at ·12,000g at 48C for 10 minutes, the supernatant was collected, and total protein concentration was determined using the BCA protein assay kit (PPLYGEN, Beijing, China). Immunoprecipitation protein extracts from cultured cells were prepared by Immunoprecipitation lysis buffer (Thermo#87787) with protein phosphatases inhibitor complex (APPLYGEN). The lysates were centrifuged for 10 minutes at 13,000 rpm at 48C, and supernatants was incubated with E-cadherin (CST) or IgG (Santa cruz) for 2 hours, followed by incubation with protein G/A agarose beads (Santa Cruz) overnight. The beads were washed using phosphatebuffered saline buffer 3 times, and then boiled in SDS loading buffer. Lysates or immunoprecipitates was separated on 10% SDS-PAGE gel and transferred to polyvinylidene difluoride membranes. The membranes were probed overnight at 48C with 
Statistics Analysis
Statistical analysis was performed using the Prism statistical package. Tukey's t test was used to compare data between 2 groups. Values were expressed as mean 6 SEM. Values of P , 0.05 were considered statistically significant.
RESULTS
Effects of Vitamin D 3 on Tumor Formation in AOM-DSS Mouse Model
First, an AOM-DSS-induced colitis-associated colon cancer model was established with incidence rate of almost 100% (Fig. 1A) ( Table 1) . As shown by hematoxylin and eosin stain, most of the lesions in the colon were consistent with high-grade intraepithelial neoplasia or carcinoma in situ (Fig. 1B) . There were no significant differences in histological distribution after vitamin D supplement. Colonic neoplasm was most frequently observed in the middle and distal colon (Fig. 1C) . To evaluate the chemopreventive effect of vitamin D 3 , mice were divided into 6 groups (Fig. 1A) . CAC was induced in group 2 to 6 with AOM and DSS treatment except for group 1, which served as naive control. Two weeks before AOM injection, the mice in group 3 to 5 started to receive vitamin D 3 at different doses (15, 30, 60 IU$g 21 $w 21 ), whereas the mice in group 6 (post 60) began to receive vitamin D 3 at the highest dose (60 IU$g 21 $w 21 ) right after DSS treatment. Administration of vitamin D 3 (15, 30, 60, or after 60 IU$g 21 $w 21 ) significantly reduced the number (Fig.  1D ) and the burden (Fig. 1E ) of colorectal neoplasms by 33% to 63% and 42% to 59%, respectively (Table 1) . However, there was no significant difference on the distribution of tumor size between vitamin D 3 groups and the control group (Fig. 1F) . In addition, the shortening of colon length induced by AOM-DSS was abolished by the supplement of vitamin D 3 in a dose-dependent manner (Table1). The increase of the colon weight/length ratio induced by AOM-DSS was slightly alleviated after receiving vitamin D 3 (Table 1 ). These results indicate that administration of vitamin D 3 significantly reduces tumor formation induced by AOM-DSS in mice.
Evaluation of Systemic Toxicity of Vitamin D 3 Intake in Mice
Systemic toxicity was evaluated in mice after long-term administration of vitamin D 3. First, there was no obvious difference observed during the entire period of drug treatment with regard to general appearance. The supplement of vitamin D 3 did not show any adverse effect on body weight compared with AOM-DSS control group (Fig. 2A) . The serum level of 25 (OH)D 3 dramatically dropped after AOM-DSS, and it was rescued by supplemental vitamin D 3 in a dose-dependent manner (Fig. 2B) , although the serum levels of calcium and creatinine remained relatively stable (Fig. 2C, D) . To evaluate the toxicity of long-term vitamin D on healthy mice, the vitamin D only group was included. The data showed that the level of serum 25(OH)D 3 in healthy mice was slightly increased compared with AOM-DSS mice after long-term administration of vitamin D (60 IU$g 21 $w 21 ) (Fig. 2B) , whereas the level of calcium in the serum did not change (Fig. 2C) . All the data suggest that the dosage of vitamin D 3 used in the current study significantly rescues and increases the serum levels of vitamin D 3 without showing any systemic toxicity in mice at the end of the experimental procedure.
Vitamin D 3 Reduces Cell Proliferation in Colon
To evaluate the effect of vitamin D 3 on cell proliferation in colorectal mucosa, Ki-67 staining was performed. It was noticed that, compared with the AOM-DSS control group, vitamin D 3 (15, 30 , 60, or after 60 IU$g 21 $w 21 ) significantly inhibited colonic cell proliferation by 17%, 35%, 41%, and 36%, respectively (Fig. 3A, B) . In vitro, treatment with 1a,25(OH) 2 D 3 in SW480 cells decreased cell growth in a time-and dose-dependent manner as measured by MTT assay (Fig. 3C) . These data suggest that vitamin D 3 directly inhibits colonic cell proliferation.
Vitamin D 3 Reduces b-catenin Activity in Vivo
Wnt/b-catenin is the core signaling pathway in colonic carcinogenesis and plays an important role in the control of cell proliferation through its downstream target genes including cyclin D1. Vitamin D 3 administration at all dosages decreased the level of b-catenin mRNA, which was dramatically upregulated in colonic tissue after the induction of CAC by AOM-DSS (Fig. 4A) . Immunostaining data showed the upregulation of b-catenin protein in the cytoplasm of the epithelium after AOM-DSS treatment, especially in dysplasia areas (Fig. 4B) . A significant decrease in the expression of b-catenin was noted after the treatment with vitamin D 3 , and the most significant decrease was observed in the high-dose vitamin D 3 (60 IU$g 21 $w 21 ) group (Fig. 4B) . Consistent with this, the mRNA level of cyclin D1, a main transcriptional target gene of b-catenin, increased after CAC induction and was reduced by the supplement of vitamin D 3 (Fig. 4C) , suggesting that vitamin D 3 suppresses the activation of b-catenin in CAC. (Fig. 5A) . However, the amounts of b-catenin mRNA and protein were not affected by 1a,25(OH) 2 D 3 (Fig. 5B, C) . Remarkably, the level of b-catenin in the nuclear fraction was attenuated by 1a,25 (OH) 2 D 3 in SW480 cells (Fig. 5D ).
1a,25(OH) 2 D 3 Enhances the Binding of b-catenin to E-cadherin
Interestingly, we observed that expression of E-cadherin protein was elevated after treatment with 1a,25(OH) 2 D 3 for 48 hours (Fig. 5B) . It is well known that E-cadherin forms a complex with b-catenin on the cell membrane, where it inhibits the nuclear translocation of b-catenin. 12 As shown by immunoprecipitation, administration of 1a,25(OH) 2 D 3 dramatically enhanced the binding of E-cadherin to b-catenin (Fig. 5E ). These findings suggest that E-cadherin-mediated sequestration of b-catenin in the cytoplasm might partly contribute to vitamin D-related suppression of b-catenin activity.
E-cadherin Related to Protective Role of Vitamin D 3 In Vivo
Finally, it was found that E-cadherin expression in colonic tissue was inhibited at both the mRNA and protein levels with the formation of CAC in mice (Fig. 6A-C) . These 
DISCUSSION
Vitamin D and its analogs are shown to inhibit colon carcinogenesis in many animal models. Newmark et al reported that supplementation of vitamin D, combined with calcium, decreases both incidence and multiplicity of tumor in a Westernstyle diet-induced colon cancer model. 13 Apc min mice, a mouse model of intestinal carcinogenesis, develop multiple intestinal neoplasias throughout the intestinal tract within weeks after birth. A significant decrease in total tumor load over the entire gastrointestinal tract is observed when 1a,25(OH) 2 D 3 or an analog was given by i.p. injection. 14 With regard to CAC, Hummei et al reported that increasing dietary vitamin D intake leads to the prevention of preneoplastic lesions induced by AOM-DSS treatment. 15 However, it was preneoplastic lesions, rather than tumor formation, that was used as a parameter to assess the preventive role of vitamin D on CAC. In the current study, we showed that supplemental vitamin D 3 dose-dependently prevented AOM-DSS-induced colonic carcinogenesis in terms of the tumor number and tumor burden without affecting tumor size. It has been shown previously that proinflammatory cytokines serve as tumor growth factors. Inactivation of NF-kB (a key transcriptional factor in inflammation) in myeloid cells results in a significant decrease of tumor size in CAC model. 11 These findings suggest that the degree of inflammation is closely associated with the size of tumor. This is consistent with previous reports 5, 16 that systemic administration of vitamin D shows an anti-inflammatory effect on acute colonic inflammation induced by 5-day DSS treatment as measured with mRNA expression of TNF-a and IL-6 (data not show). However, in the current study, the colon tissue of mice treated with AOM-DSS was collected 12 weeks after DSS treatment (Fig. 1A) . At this time point, supplemental vitamin D did not show any significant effect on chronic inflammation and the mucosal cytokine mRNA expression (data not shown). These might partly explain why, in this study, there was no significant effect of vitamin D on the size of tumor in CAC. Moreover, it is worthy of note that administration of vitamin D 3 after the induction of AOM-DSS (after 60 group) was still able to prevent the formation of CAC. It strongly indicates that vitamin D 3 is a potential chemopreventive drug for CAC in patients with IBD.
The Endocrine Society Committee recommended 50,000 IU of vitamin D once weekly for 8 weeks for treatment of vitamin D deficiency (25[OH]D 3 , 20 ng/mL). 17 The dosage (15, 30 , and 60 IU$g 21 $w 21 ) of vitamin D 3 used in our study equals to 100,000, 200,000, and 400,000 IU/w for human recommendation, respectively. Although hypercalcinemia and renal dysfunction were not observed in any intervention groups, further preclinical study is required to determine the appropriate amount of dietary vitamin D 3 for patients with IBD.
Our study showed that vitamin D 3 
